Literature DB >> 1695369

Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry.

H Schulze1, S Claus.   

Abstract

The role of estrogens and estrogen receptors (ER) in the human prostate remains unresolved. In this study we have used the monoclonal ER antibody H222 to investigate the histological localization of ER in normal and diseased human prostates by immunocytochemistry. Prostate tissue was obtained from 3 young organ donors (Group I-normal prostate), from 14 prostates removed by radical prostatectomy or radical cystoprostatectomy, which had caused no or only mild obstructive symptoms (Group II-non-obstructive prostate), and from 11 prostates removed by suprapubic prostatectomy, which had caused severe obstructive symptoms due to a large benign prostatic hyperplasia (BPH) (Group III-obstructive prostate). In prostates of all groups ER were found to be in nuclei of the prostatic urethra and of the periurethral prostatic duct. In striking contrast, ER in the interglandular prostatic stroma was not as homogeneous among the different groups. We observed a low concentration of ER in the stroma of normal prostates, the highest concentration in non-malignant stroma of non-obstructive prostates, and no ER at all in stroma of obstructive prostates. Based on the immunocytochemical localization of ER in normal and diseased human prostate, our results indicate that stromal growth in obstructive BPH may not be mediated via ER. However, we cannot exclude that an increase of stromal ER concentration (as observed in non-obstructive prostates) is directly involved in induction of BPH, leading further prostate growth thereafter into an estrogen independent state.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695369     DOI: 10.1002/pros.2990160408

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  15 in total

1.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.

Authors:  I Leav; K M Lau; J Y Adams; J E McNeal; M E Taplin; J Wang; H Singh; S M Ho
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  The role of estrogens and estrogen receptors in normal prostate growth and disease.

Authors:  Gail S Prins; Kenneth S Korach
Journal:  Steroids       Date:  2007-11-12       Impact factor: 2.668

3.  Steroid receptor profile and receptor stability in subfractions of human prostatic tissues. Critical aspects on microassays.

Authors:  J Brolin; L Andersson; P Ekman
Journal:  Urol Res       Date:  1991

4.  Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.

Authors:  Zongwei Wang; Libing Hu; Keyan Salari; Seth K Bechis; Rongbin Ge; Shulin Wu; Cyrus Rassoulian; Jonathan Pham; Chin-Lee Wu; Shahin Tabatabaei; Douglas W Strand; Aria F Olumi
Journal:  J Pathol       Date:  2017-12       Impact factor: 7.996

Review 5.  Estrogens in Male Physiology.

Authors:  Paul S Cooke; Manjunatha K Nanjappa; CheMyong Ko; Gail S Prins; Rex A Hess
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

6.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.

Authors:  H Bonkhoff; T Fixemer; I Hunsicker; K Remberger
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

7.  Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Authors:  Tristan M Nicholson; Priyanka D Sehgal; Sally A Drew; Wei Huang; William A Ricke
Journal:  Differentiation       Date:  2013-06-20       Impact factor: 3.880

8.  Inhibition of growth and cell cycle arrest of ARCaP human prostate cancer cells by ectopic expression of ER-alpha.

Authors:  Q Ye; B Cinar; M Edlund; L W Chung; H E Zhau
Journal:  Mol Cell Biochem       Date:  2001-12       Impact factor: 3.396

9.  Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia.

Authors:  A A Geldof; C Engel; B R Rao
Journal:  Urol Res       Date:  1992

Review 10.  Endocrine disruptors and prostate cancer risk.

Authors:  Gail S Prins
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.